Medically reviewed by Dr. Andrew Stein, Consultant Nephrologist: Last updated April 2026
For survivors of an ischaemic stroke or ‘mini-stroke’ (TIA), the first 72 hours are critical, yet the threat of recurrence remains a constant shadow. A landmark study involving 12,327 patients, published on April 15, 2026, in the New England Journal of Medicine (Sharma, 2026), has introduced an important medication called asundexian.
This new drug offers a ‘smarter’ way to thin the blood, successfully reducing the risk of a second stroke by 26%. By targeting a specific protein called Factor XIa, asundexian prevents the ‘bad’ clots that cause strokes while allowing the body to maintain its natural ability to stop bleeding from injuries.
The OCEANIC-STROKE trial solved a decades-old medical dilemma: how to provide stronger protection without increasing the risk of dangerous internal bleeding. Traditionally, more powerful blood thinners have meant a higher chance of life-threatening haemorrhages.
However, this study found that patients taking asundexian had no significant increase in major bleeding compared to those taking a placebo.
In fact, major bleeding rates were nearly identical—1.9% for asundexian versus 1.7% for the placebo group. This ‘safety first’ profile makes it a potential lifesaver for patients with atherosclerosis (clogged arteries) who need extra protection without an increased risk of bleeding.
Comparing Asundexian to Traditional Treatments
For more context on how this fits into existing care, you may find these MyHSN resources helpful:
The clinical data confirms that asundexian provides a robust treatment to prevent stroke. Interestingy, the drug also lowered the overall risk of heart attacks and cardiovascular death (9.2% vs. 11.1% in the placebo group).
Because the drug was well-tolerated—with overall adverse event rates actually slightly lower than the placebo (69.3% vs. 70.1%) —it is expected to move quickly through regulatory channels.
For millions of survivors, this discovery represents a shift toward more precise prevention, where the medicine is powerful enough to protect the brain without increased bleeding risk.
| Outcome Category | Asundexian (50 mg) | Placebo | Hazard Ratio (95% CI) |
| Recurrent Ischaemic Stroke | 6.2% | 8.4% | 0.74 (0.65–0.84) |
| CV Death, MI, or Stroke | 9.2% | 11.1% | 0.83 (0.74–0.92) |
| Major Bleeding | 1.9% | 1.7% | 1.10 (0.85–1.44) |
Further Reading from MyHSN
To learn more about stroke recovery and cardiovascular health, please visit:
